Producers Online
SELSKABSMEDDELELSE nr. 68 - 16. september 2024 Den 9. februar 2024 meddelte DFDS A/S (“DFDS”) iværksættelsen af et aktietilbage-købsprogram til gennemførsel i henhold til EUs markedsmisbrugsforordning, EU forordning nr. 596/2014…
- Un taux de réponse objective (TRO) cliniquement significatif de 63,3–76,7 % a été observé avec l’association belrestotug + dostarlimab, avec un TRO confirmé (TROc) d'environ 60 % pour chaque…
- Klinisch bedeutsame objektive Ansprechrate (Objective Response Rate, ORR) von 63,3–76,7 % bei der Kombination von Belrestotug + Dostarlimab, mit einer bestätigten ORR (confirmed ORR, cORR) von ca. 60 %…
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12),…
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human genetics correlated with increased clinical benefit,…
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and a subset…
Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose expansion cohortResponses with Rina-S were observed…
Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints of overall survival, but did not meet statistical significanceIpsen will…
L’essai portant sur Cabometyx® (cabozantinib) en association avec l’atézolizumab a démontré une tendance positive à l’amélioration de l’un des critères d’évaluation principaux de la survie globale, sans atteindre la significativité…
Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses Patients demonstrated…